Kairos Pharma (NYSEAMERICAN:KAPA) Stock Price Down 4.2% – Here’s What Happened

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) shares dropped 4.2% during mid-day trading on Tuesday . The company traded as low as $0.4303 and last traded at $0.4310. Approximately 85,238 shares changed hands during trading, a decline of 52% from the average daily volume of 176,798 shares. The stock had previously closed at $0.45.

Kairos Pharma Trading Down 4.2%

The firm has a 50-day simple moving average of $0.55 and a two-hundred day simple moving average of $0.65. The company has a market capitalization of $9.23 million, a price-to-earnings ratio of -1.44 and a beta of 1.36.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter. On average, sell-side analysts forecast that Kairos Pharma, Ltd. will post -0.37 earnings per share for the current year.

Institutional Trading of Kairos Pharma

Several large investors have recently made changes to their positions in KAPA. XTX Topco Ltd acquired a new position in shares of Kairos Pharma during the 2nd quarter valued at about $44,000. Two Sigma Investments LP acquired a new stake in Kairos Pharma in the 3rd quarter worth approximately $54,000. Finally, FNY Investment Advisers LLC acquired a new stake in Kairos Pharma in the 3rd quarter worth approximately $27,000.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.